Bisphosphonates, specifically Zometa, is commonly used in the treatment of men with advanced prostate cancer. Zometa is used to treat and protect bones from developing fractures. Bisphosphonates are potent inhibitors of bone resorption. Additionally, in vitro studies show that zolendronic acid also inhibits prostate cancer cell growth by activating apoptosis (A form of cell death [...]
As we all anxiously wait for the FDA to finally make a determination about the pending application for approval of the investigational androgen biosynthesis inhibitor abiraterone acetate more data rolls in showing that supports the need to have a speedy approval. A new study published March 1, 2011, out of Italy adds support to the [...]
A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer. The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, [...]
In prior studies with men who have had a PSA recurrence after radiotherapy (RT), intermittent androgen suppression (IAS) has been suggested to improve quality of life (QoL) but effects on survival are unknown. The researchers performed an inter-group randomized phase III trial, which compared IAS vs continuous androgen deprivation (CAD) to test overall survival (OS) [...]
An article appearing today the Urology Times E-News rang a warning bell about the use of the angiogenesis inhibitor bevacizumab (Avastin). The article warned that men with advanced prostate cancer may be at an increased risk of treatment-related death when bevacizumab is used in combination with other therapies. Senior author Shenhong Wu, MD, PhD, and [...]
Prostate cancer diets and the use of supplements have continued to be an issue faced by men fighting advanced prostate cancer. Different products seem to fall in and out of vogue; unfortunately we usually have little actual hard data on the real value of any of these products. The use of pomegranate with the goal [...]
We have been having a lot of conversations on the advanced prostate cancer on-line group this last month about chemotherapy. Three of our advanced prostate cancer warriors have been openly sharing their experiences as they start docetaxel (taxotere or chemotherapy). Join the group at: Join the advanced prostate cancer on-line support group. It is important [...]
Can IxMP Be Used as a Second or Third-Line Chemotherapy for Metastatic Castrate Resistant Prostate Cancer? There was a report recently released about a Phase 2 study from the Department of Defense funded Prostate Cancer Clinical Trials Consortium that suggests that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of [...]
